Antibody-Conjugated Nanoparticles for Targeted Gene Editing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current gene-editing methods for hematopoietic stem cells face challenges such as cell differentiation and loss of homing potential, lack of precise markers for isolation, severe toxicities in pre-transplant conditioning, and limited access due to the need for specialized healthcare centers, along with cellular toxicity from existing delivery methods like electroporation and viral transduction.
Innovation Solution
Development of an antibody conjugate comprising an antibody and a nanoparticle with a gene-editing payload, specifically targeting CD34 and Gpr56 markers on hematopoietic stem cells using high-affinity antibodies and biodegradable PLGA nanoparticles to enhance delivery and reduce toxicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If electroporation or viral transduction is used to deliver CRISPR to HSPCs, then gene-editing efficiency is improved, but cellular toxicity increases
Solution Approach 1:
The patent uses antibody-conjugated nanoparticles as an intermediary delivery system. The nanoparticles encapsulate CRISPR components and are targeted to HSPCs via antibody binding to cell surface markers (CD34, gpr56). This intermediary approach avoids the direct cellular stress of electroporation and viral infection, reducing toxicity while maintaining delivery efficiency.
Solution Approach 2:
The patent changes the delivery parameters from direct physical/viral methods to a targeted nanoparticle system. By controlling nanoparticle size, surface charge, and antibody conjugation, the delivery becomes more selective and less toxic. The biodegradable PLGA material allows controlled release of CRISPR components, optimizing the delivery parameters for both efficiency and safety.
2Productivity
If CD34 is used to isolate HSCs from blood and bone marrow, then HSC isolation is achieved, but a heterogeneous cell population including immune and endothelial cells is obtained
Solution Approach 1:
The patent segments the targeting approach by using dual-specificity antibodies that can recognize multiple markers (CD34 and gpr56). This segmentation of the targeting strategy allows for more precise isolation by combining the benefits of both markers, separating true HSCs from heterogeneous CD34+ cells that include immune and endothelial cells.
Solution Approach 2:
The patent employs antibodies with multi-functionality, particularly dual-specificity antibodies that can bind to both CD34 and gpr56 markers. This multi-functional approach allows a single antibody or antibody mixture to achieve both the productivity of CD34 targeting and the precision of gpr56-specific HSC identification, resolving the contradiction between isolation efficiency and population purity.
3Productivity
If pre-transplant conditioning is used to make space for engraftment of isolated and reinfused HSCs, then engraftment space is created, but severe acute toxicities in multiple organs occur
Solution Approach 1:
The patent extracts the need for harsh pre-transplant conditioning by enabling direct in vivo gene editing of HSPCs. By delivering CRISPR components directly to HSPCs in the patient using targeted nanoparticles, the therapy can be performed without removing cells ex vivo and without requiring myeloablastic conditioning, thus eliminating the toxicities while maintaining engraftment capability.
Solution Approach 2:
The patent performs preliminary gene editing of HSPCs in vivo before transplantation needs to occur. By editing the genes directly in the patient's HSPCs using targeted nanoparticle delivery, the corrective action is taken beforehand, eliminating the need for subsequent conditioning and transplantation procedures that cause organ toxicities.
4Reliability
If ex-vivo gene-editing of HSCs is performed in specialized health-care centres, then gene-editing therapy is provided, but access is limited for patients in less developed parts of the world
Solution Approach 1:
The patent enables the patient's own HSPCs to serve as the delivery target for gene editing. The autologous HSPCs are edited in vivo using systemically administered nanoparticles that self-target to the patient's cells. This self-service approach eliminates the need for specialized centers to perform complex ex vivo manipulation, allowing therapy to be delivered in standard clinical settings and improving global accessibility.
5Productivity
If high-affinity classical antibodies (H2L2 Abs) are used to enhance endocytic capacity in HSPCs, then targeting efficiency is improved, but the risk of immune reaction increases
Solution Approach 1:
The patent changes the antibody parameter from classical H2L2 structure to heavy-chain only antibody format. This structural parameter change maintains high affinity and targeting efficiency while using human-derived sequences that reduce immunogenicity. The VH-region alone or heavy-chain only antibodies provide the necessary binding capability without the light chain components that may contribute to immune recognition.
Solution Approach 2:
The patent creates a composite antibody-nanoparticle system where human-derived antibody fragments (VH or heavy-chain only) are conjugated to biodegradable PLGA nanoparticles. This composite structure combines the targeting efficiency of high-affinity antibodies with the biocompatibility and controlled release properties of PLGA, achieving both high productivity and reduced immune reaction risk through the synergistic combination of materials.
Data Source
AI summary
The invention relates to antibody conjugates comprising an antibody and a nanoparticle conjugated to the antibody, wherein the nanoparticle comprises a payload, such as a gene editing payload. In some embodiments, the antibody-conjugated nanoparticles provide a means for treating a disease. In some embodiments, the antibody-conjugated nanoparticles are used to correct genetic defects in specific cell populations.